Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rusalatide - Chrysalis BioTherapeutics

Drug Profile

Rusalatide - Chrysalis BioTherapeutics

Alternative Names: Chrysalin; Rusalatide acetate; Thrombin receptor activating peptide; TP 508; TRAP-508

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas Medical Branch
  • Developer Baylor College of Medicine; Capstone Therapeutics; Chrysalis BioTherapeutics; Quintiles; University of Texas Medical Branch
  • Class Peptides; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Apoprotein inhibitors; Apoptosis inhibitors; Cytokine modulators; Intercellular signalling peptide and protein stimulants; Nitric oxide stimulants; Osteogenesis stimulants; Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute radiation syndrome
  • Discontinued Chronic wounds; Diabetic foot ulcer; Fracture; Joint disorders; Myocardial infarction; Periodontal disorders; Spinal disorders; Vascular disorders

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for preclinical development in Acute-radiation-syndrome in USA (Parenteral, Injection)
  • 27 Aug 2019 Chrysalis BioTherapeutics plans preclinical efficacy studies in Acute radiation syndrome
  • 21 Aug 2019 Rusalatide receives Orphan Drug status for Acute radiation syndrome in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top